Beaver Announces Completion of ￥10 Million Series B Funding Round

(VCBeat) Apr. 21, 2021 -- Suzhou Beaver Biomedical Engineering Co., Ltd. ("Beaver"), a leading company in the field of magnetic nanobeads, has recently completed a Series B round of financing worth tens of millions, co-led by Clivia Capital and CM Venture Capital, with participation from Shenzhen Huihe Capital and Junzi Jing Investment.

The funds are earmarked for continuing the support of Beaver's large-scale production of the third generation of chemiluminescence and immunocapture magnetic beads, the in-depth development of the fourth generation of advanced manufacturing technology of magnetic nanobeads, expansion of the global market, and construction of the industrialization base of biomedical products based on the core technology of magnetic nanobeads, and the improvement of the ability to automate the whole clinical and non-clinical biological sample processing.

Beaver is founded by Dr.Ren Hui returned to stay in the United States, with international advanced biological nano surface technology and efficient biological reagent technology as the core, focusing on the development of high-end cell culture, specific markers and capture, rapid separation and purification of proteins, nucleic acid extraction and library construction, and high flux, automation biological sample processing integrated technology platform, has now developed into a collection of independent research and development, production and sales of large-scale high-tech enterprise services in biomedical engineering.

At present, Beaver has built a production base of nearly 6000 square meters. For biomedical research and IVD, the company provides magnetic beads for protein purification, nucleic acid extraction, and chemiluminescent immunoassay, forming a complete set of more than 20 products covering biological sample collection, preservation, extraction of biological reagents in the whole process, biological consumables, automation equipment and so on.

Founded in January 2015, Clivia Capital is a cutting-edge professional investment institution, headquartered in Suzhou, with an AUM of over 1 billion yuan. It focuses on the fields of health care, new materials, semiconductors, and so on. Clivia Capital mainly invests in high-quality entrepreneurial projects from Peking University alumni, including but not limited to strategic emerging fields such as bio-medicine, medical devices, new materials, intelligent manufacturing, etc.

CM Venture Capital is a strategic investment fund with a deep industry background that invests in hard technology companies that create industrial transformations. They have a global portfolio of hard technology companies, from Asia to North America to Europe, engaged in developing advanced materials and manufacturing processes, industrial digitization, artificial intelligence and IoT solutions, clean energy, and technologies and products that accelerate carbon neutrality.